当前位置:
X-MOL 学术
›
J. Cancer Res. Ther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Overexpression of replication protein A3 is associated with unfavorable outcome in bladder urothelial carcinoma
Journal of Cancer Research and Therapeutics ( IF 1.3 ) Pub Date : 2021-07-01 , DOI: 10.4103/jcrt.jcrt_275_21 Dingqi Sun 1 , Keqin Zhang 1 , Qiang Fu 1 , Hui Zhang 1 , Shuai Liu 1 , Haoran Wang 2 , Zhen Xu 2 , Jinhua Wang 3
Purpose: The replication protein A3 (RPA3) is a subunit of the RPA protein complex, which plays an essential role in multiple processes of DNA metabolism. However, the involvement of RPA3 bladder urothelial carcinoma (UC) prognosis has not yet been elucidated. The aim of our study is to investigate the prognostic role of RPA3 expression in patients with bladder UC.
Materials and Methods: Bladder UC tissue specimens from 155 consecutively treated patients who underwent surgery between 2013 and 2018 were evaluated. The RPA3 expression was determined by immunohistochemistry, Western blot, and correlated with clinicopathological parameters. The prognostic significance of RPA3 expression was explored using the univariate and multivariate survival analysis of 155 patients who were followed.
Results: A total of 155 tissue specimens “of patients” who were regularly followed with the mean 39.6 months (from 4 to 71 months). The expression of RPA3 was significantly associated with tumor grade (P = 0.031) and stage (P = 0.021), as well as tumor size (P = 0.034). In univariate analysis, RPA3 overexpression showed an unfavorable influence on recurrence-free survival with statistical significance (P < 0.01). TNM stage and grade also showed strong statistical relation with adverse recurrence-free survival (P < 0.01, P = 0.030). Multivariate analysis revealed that grade, stage, and RPA3 reactivity (P = 0.025, P < 0.01, P = 0.016) were identified as independent prognostic factors for recurrence-free survival in patients with bladder UC.
Conclusions: These results of this study proved that elevated expression of RPA3 was associated with worse clinical outcome in bladder UC patients. This finding suggested that RPA3 served as a potential prognostic biomarker, which could be useful to predict cancer evolution and may represent a novel therapeutic target for the intervention of bladder UC patients.
中文翻译:
复制蛋白 A3 的过表达与膀胱尿路上皮癌的不良结果相关
目的:复制蛋白A3(RPA3)是RPA蛋白复合物的一个亚基,在DNA代谢的多个过程中起重要作用。然而,RPA3 对膀胱尿路上皮癌(UC)预后的影响尚未阐明。我们研究的目的是研究 RPA3 表达在膀胱 UC 患者中的预后作用。
材料和方法:评估了 2013 年至 2018 年间接受手术的 155 名连续治疗患者的膀胱 UC 组织标本。通过免疫组织化学、Western blot 确定 RPA3 表达,并与临床病理参数相关。使用随访的 155 名患者的单变量和多变量生存分析探讨了 RPA3 表达的预后意义。
结果:共有 155 份“患者”组织标本进行了定期随访,平均随访时间为 39.6 个月(4 至 71 个月)。RPA3的表达与肿瘤分级(P = 0.031)和分期(P = 0.021)以及肿瘤大小(P = 0.034)显着相关。单因素分析显示,RPA3过表达对无复发生存期有不利影响,具有统计学意义(P <0.01)。TNM分期和分级也与不良无复发生存期有很强的统计学相关性(P < 0.01,P = 0.030)。多变量分析显示分级、分期和 RPA3 反应性 ( P = 0.025, P< 0.01, P = 0.016) 被确定为膀胱 UC 患者无复发生存的独立预后因素。
结论:本研究的这些结果证明,RPA3 的表达升高与膀胱 UC 患者的较差临床结果相关。这一发现表明,RPA3 可作为潜在的预后生物标志物,可用于预测癌症演变,并可能代表膀胱 UC 患者干预的新治疗靶点。
更新日期:2021-07-12
Journal of Cancer Research and Therapeutics ( IF 1.3 ) Pub Date : 2021-07-01 , DOI: 10.4103/jcrt.jcrt_275_21 Dingqi Sun 1 , Keqin Zhang 1 , Qiang Fu 1 , Hui Zhang 1 , Shuai Liu 1 , Haoran Wang 2 , Zhen Xu 2 , Jinhua Wang 3
Affiliation
Purpose: The replication protein A3 (RPA3) is a subunit of the RPA protein complex, which plays an essential role in multiple processes of DNA metabolism. However, the involvement of RPA3 bladder urothelial carcinoma (UC) prognosis has not yet been elucidated. The aim of our study is to investigate the prognostic role of RPA3 expression in patients with bladder UC.
Materials and Methods: Bladder UC tissue specimens from 155 consecutively treated patients who underwent surgery between 2013 and 2018 were evaluated. The RPA3 expression was determined by immunohistochemistry, Western blot, and correlated with clinicopathological parameters. The prognostic significance of RPA3 expression was explored using the univariate and multivariate survival analysis of 155 patients who were followed.
Results: A total of 155 tissue specimens “of patients” who were regularly followed with the mean 39.6 months (from 4 to 71 months). The expression of RPA3 was significantly associated with tumor grade (P = 0.031) and stage (P = 0.021), as well as tumor size (P = 0.034). In univariate analysis, RPA3 overexpression showed an unfavorable influence on recurrence-free survival with statistical significance (P < 0.01). TNM stage and grade also showed strong statistical relation with adverse recurrence-free survival (P < 0.01, P = 0.030). Multivariate analysis revealed that grade, stage, and RPA3 reactivity (P = 0.025, P < 0.01, P = 0.016) were identified as independent prognostic factors for recurrence-free survival in patients with bladder UC.
Conclusions: These results of this study proved that elevated expression of RPA3 was associated with worse clinical outcome in bladder UC patients. This finding suggested that RPA3 served as a potential prognostic biomarker, which could be useful to predict cancer evolution and may represent a novel therapeutic target for the intervention of bladder UC patients.
中文翻译:
复制蛋白 A3 的过表达与膀胱尿路上皮癌的不良结果相关
目的:复制蛋白A3(RPA3)是RPA蛋白复合物的一个亚基,在DNA代谢的多个过程中起重要作用。然而,RPA3 对膀胱尿路上皮癌(UC)预后的影响尚未阐明。我们研究的目的是研究 RPA3 表达在膀胱 UC 患者中的预后作用。
材料和方法:评估了 2013 年至 2018 年间接受手术的 155 名连续治疗患者的膀胱 UC 组织标本。通过免疫组织化学、Western blot 确定 RPA3 表达,并与临床病理参数相关。使用随访的 155 名患者的单变量和多变量生存分析探讨了 RPA3 表达的预后意义。
结果:共有 155 份“患者”组织标本进行了定期随访,平均随访时间为 39.6 个月(4 至 71 个月)。RPA3的表达与肿瘤分级(P = 0.031)和分期(P = 0.021)以及肿瘤大小(P = 0.034)显着相关。单因素分析显示,RPA3过表达对无复发生存期有不利影响,具有统计学意义(P <0.01)。TNM分期和分级也与不良无复发生存期有很强的统计学相关性(P < 0.01,P = 0.030)。多变量分析显示分级、分期和 RPA3 反应性 ( P = 0.025, P< 0.01, P = 0.016) 被确定为膀胱 UC 患者无复发生存的独立预后因素。
结论:本研究的这些结果证明,RPA3 的表达升高与膀胱 UC 患者的较差临床结果相关。这一发现表明,RPA3 可作为潜在的预后生物标志物,可用于预测癌症演变,并可能代表膀胱 UC 患者干预的新治疗靶点。